Skip to main content
SpringerLink
Log in

A review of the Augustine blood group system

  • Review Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Augustine is a newly identified blood group system comprising four antigens, one of which is the high-frequency antigen Ata in the original “series”. Four antigens are located on a multipass membrane glycoprotein equilibrative nucleoside transporter 1 (ENT1), and equilibrative nucleoside transporter is encoded by SLC29A1. In 2016, the International Society of Blood Transfusion (ISBT) recognised Augustine as a blood group system and numbered it as 036. The glycoprotein ENT1 transports nucleotides into cells to participate in the synthesis of DNA and RNA, and this is an important link for chemotherapeutic glycosides to enter tumour cells. Augustine antibodies are clinically relevant in blood transfusion and pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Baloch K, Chen L, et al. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother. 2017;25(1):2–10.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Giovannetti E, Leon LG, et al. A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):643–51.

    Article  CAS  PubMed  Google Scholar 

  3. Zafar M, Naydenova Z, et al. Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1). Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):631–42.

    Article  CAS  PubMed  Google Scholar 

  4. Wu L, Shi W, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14(1):66.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yamada R, Mizuno S, et al. Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy. Pancreas. 2016;45(5):761–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cass CE, Paterson AR. Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants. J Biol Chem. 1972;247(10):3314–20.

    Article  CAS  PubMed  Google Scholar 

  7. Kuttesch JF Jr, Robins MJ, et al. Renal transport of 2’-deoxytubercidin in mice. Biochem Pharmacol. 1982;31(21):3387–94.

    Article  CAS  PubMed  Google Scholar 

  8. Belt JA, Welch AD. Transport of uridine and 6-azauridine in human lymphoblastoid cells Specificity for the uncharged 6-azauridine molecule. Mol Pharmacol. 1983;23(1):153–8.

    CAS  PubMed  Google Scholar 

  9. Daniels G. The Augustine blood group system, 48 years in the making. Immunohematology. 2016;32:100–3.

    Article  PubMed  Google Scholar 

  10. Damaraju VL, Weber D, et al. Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL Kinase Inhibitors: identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitorS. J Biol Chem. 2016;291(36):18809–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Panigrahi R, Dash S. ENT1 and treatment of viral diseases. Oncotarget. 2015;6(32):32281–2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Aseervatham J, Tran L, et al. The role of flexible loops in folding, trafficking and activity of equilibrative nucleoside transporters. PLoS ONE. 2015;10(9):e0136779.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wan H, Zhu J, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33(1):90.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tavano F, Fontana A, et al. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. Pancreatology. 2014;12(1):1–11.

    Google Scholar 

  15. Ormanns S, Heinemann V, et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur J Cancer. 2014;50(11):1891–9.

    Article  CAS  PubMed  Google Scholar 

  16. Zhu Y, Qi M, et al. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomark. 2014;18(5):306–12.

    Article  CAS  Google Scholar 

  17. Furihata T, Mizuguchi M, et al. Identification of primary equilibrative nucleoside transporter 1 mRNA isoforms resulting from alternative promoter usage in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):325–32.

    Article  CAS  PubMed  Google Scholar 

  18. Liu ZQ, Liu ZQ, et al. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS ONE. 2014;9(1):e87103.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mohelnikova-Duchonova B, Melichar B. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology. 2013;13(6):558–63.

    Article  CAS  PubMed  Google Scholar 

  20. Wei CH, Gorgan TR, et al. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 2013;42(8):1303–10.

    Article  CAS  PubMed  Google Scholar 

  21. Suzuki Y, Homma M, et al. Impact of solute carrier family 29 member 1 (SLC29A1) single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells. Biol Pharm Bull. 2013;36(1):144–6.

    Article  CAS  PubMed  Google Scholar 

  22. Daniels G. Augustine blood group system and equilibrative nucleoside transporter 1. Transfus Med Hemother. 2022;49:25–9.

    Article  PubMed  Google Scholar 

  23. Millard GM, McGowan EC, et al. A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. Transfusion. 2018;58:1320–2.

    Article  PubMed  Google Scholar 

  24. Yao SY, Ng AM, et al. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem. 2011;286(37):32552–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Guillén-Gómez E, Pinilla-Macua I, et al. New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol. 2012;227(4):1521–8.

    Article  PubMed  Google Scholar 

  26. Xu Z, Li SZ. Research progress of erythrocyte blood group antigen. Clin Hematol Transfus Testing. 2016;29(4):345–50.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Scientific Research Project of Hunan Provincial Health Commission (Grant/Award Number: 202211003190).

Funding

Scientific Research Project of Hunan Provincial Health Commission, Grant/Award Number: 202211003190.

Author information

Authors and Affiliations

  1. Department of Blood Transfusion, The Central Hospital of Shaoyang, Shaoyang, China

    Jing Zhong, Chunping Mo, Yan Zhang & Lingbo Li

  2. Changchun Bioxun Biotechnology Limited Liability Company, 285 Xinpu Road, Changchun, Jilin, China

    Yan Zhang

  3. Aikang MedTech Co., Ltd, 1A, Shijing Industrial Park, Pingkui Rd, Shijing St, Pingshan, Shenzhen, China

    Lingbo Li

Authors
  1. Jing Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunping Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lingbo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yan Zhang or Lingbo Li.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhong, J., Mo, C., Zhang, Y. et al. A review of the Augustine blood group system. Int J Hematol (2024). https://doi.org/10.1007/s12185-024-03791-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12185-024-03791-3

Keywords

Search

Navigation